Editorial: Myeloid Derived Suppressor Cells as Disease Modulators

[1]  Lin Qi,et al.  Patients’ risk factors for periprosthetic joint infection in primary total hip arthroplasty: a meta-analysis of 40 studies , 2021, BMC Musculoskeletal Disorders.

[2]  J. Klode,et al.  Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue , 2019, Science Immunology.

[3]  Yadan Wang,et al.  Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis , 2018, BMC Cancer.

[4]  J. Utikal,et al.  Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression , 2018, British Journal of Cancer.

[5]  S. Ostrand-Rosenberg.  Myeloid derived-suppressor cells: their role in cancer and obesity. , 2018, Current opinion in immunology.

[6]  C. Fenselau,et al.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment , 2018, The Journal of Immunology.

[7]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[8]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[9]  A. Al-Khami,et al.  Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer , 2016, Oncoimmunology.

[10]  B. Hylander,et al.  Stress, Metabolism and Cancer: Integrated Pathways Contributing to Immune Suppression , 2015, Cancer journal.

[11]  R. Schoen,et al.  MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study , 2012, Cancer Prevention Research.